Prostate specific antigen inhibits immune responses in vitro: A potential role in prostate cancer

被引:24
作者
Kennedy-Smith, AG [1 ]
McKenzie, JL
Owen, MC
Davidson, PJT
Vuckovic, S
Hart, DNJ
机构
[1] Christchurch Hosp, Urol Dept, Christchurch, New Zealand
[2] Canterbury Hlth Labs, Christchurch, New Zealand
[3] Christchurch Hosp, Haematol Res Grp, Christchurch, New Zealand
[4] Mater Med Res Inst, Brisbane, Qld, Australia
关键词
prostate; prostate-specific antigen; prostatic neoplasms; T-lymphocytes; immunosuppression;
D O I
10.1016/S0022-5347(05)64738-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Prostate specific antigen (PSA) is found in high concentration in prostate tissue and in semen, in which its physiological function appears to be liquefaction. In prostate cancer the peripheral PSA concentration is elevated, which may be used as a disease marker. Systemic and local immune defects have been demonstrated in prostate cancer and we postulated a role for PSA in this immunosuppression. We explored the effects of PSA on human T-lymphocyte proliferation in vitro. Materials and Methods: PSA was purified from normal seminal plasma using a modified chromatographic technique. The effect of PSA or control protein on lymphocyte responses to mitogens, tetanus toxoid and alloantigens was tested. The inhibitory effect observed was further explored by varying the time of PSA addition, denaturing PSA and including interleukin-2 and anti-PSA antibodies. Results: PSA suppressed in vitro phytohemagglutinin and alloantigen stimulated lymphocyte proliferation in a dose dependent manner. This effect was reversed by adding anti-PSA antibodies but not by interleukin-2. Conclusions: These in vitro PSA effects suggest another T-lymphocyte mediated immunosuppressive mechanism. In vivo high levels of PSA may compromise natural immune responses to cancer and current attempts at immunotherapy for prostate cancer.
引用
收藏
页码:741 / 747
页数:7
相关论文
共 29 条
[1]  
Aalamian M, 2001, PROSTATE, V46, P68
[2]  
ABLIN RJ, 1980, EUR UROL, V6, P225
[3]   Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma [J].
Adler, HL ;
McCurdy, MA ;
Kattan, MW ;
Timme, TL ;
Scardino, PT ;
Thompson, TC .
JOURNAL OF UROLOGY, 1999, 161 (01) :182-187
[4]   Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 [J].
Agrawal, B ;
Krantz, MJ ;
Reddish, MA ;
Longenecker, BM .
NATURE MEDICINE, 1998, 4 (01) :43-49
[5]   DNA-PLOIDY, SERUM PROSTATE-SPECIFIC ANTIGEN, HISTOLOGICAL GRADE AND IMMUNOHISTOCHEMISTRY AS PREDICTIVE PARAMETERS OF LYMPH-NODE METASTASES IN T1-T3/MO PROSTATIC ADENOCARCINOMA [J].
BERNER, A ;
WAERE, H ;
NESLAND, JM ;
PAUS, E ;
DANIELSEN, HE ;
FOSSA, SD .
BRITISH JOURNAL OF UROLOGY, 1995, 75 (01) :26-32
[6]   STRUCTURAL COMPARISON OF PROSTATE-SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN USING MOLECULAR MODELING [J].
BRIDON, DP ;
DOWELL, BL .
UROLOGY, 1995, 45 (05) :801-806
[7]  
Cardillo MR, 2000, ANAL QUANT CYTOL, V22, P1
[8]   In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen [J].
Correale, P ;
Walmsley, K ;
Nieroda, C ;
Zaremba, S ;
Zhu, MZ ;
Schlom, J ;
Tsang, KY .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (04) :293-300
[9]   Antiangiogenic activity of prostate-specific antigen [J].
Fortier, AH ;
Nelson, BJ ;
Grella, DK ;
Holaday, JW .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (19) :1635-1640
[10]  
Healy CG, 1998, CYTOMETRY, V32, P109, DOI 10.1002/(SICI)1097-0320(19980601)32:2<109::AID-CYTO6>3.0.CO